Home
News
Your Voice
Links
Jobs
Sitemap
Contact
YOU ARE HERE: >
Kernow Clinical Commissioning Group
>
Formulary Information
>
Information Page
Home
Drugs
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Chapters
KCC Referral
Management System
Shared Care
Guidelines
Care Home
Resources
Local Resource
Packs
Chronic Pain
in Cornwall
Diabetes Resources
Respiratory Resources
Flu Resource Pack
Patient Group Direction (PGD)
Palliative Care Resources
Search
Search Drugs
Search BNF Categories
Notes
Click to View ALL BNF
Ch1 Gastro
Ch2 Cardio
Ch3 Respiratory
Ch4 CNS
Ch5 Infections
Ch6 Endocrine
Ch7 Obs & Gynae
Ch8 Malignant Disease
Ch9 Nutrition & Blood
Ch10 Muscuskeletal
Ch11 Eye
Ch12 Ear, Nose, Oropharynx
Ch13 Skin
Ch14 Immunological
Ch15 Anaesthesia
Ch19 Other Dugs
ch20 Dressings
ch21 Appliances
ch22 Incontinence appliances
ch23 Stoma appliances
>>
1. Drugs Used In Diabetes
2. Thyroid And Antithyroid Drugs
3. Corticosteroids (Endocrine)
4. Sex Hormones
5. Hypothalamic&Pituitary Hormones&Antioest
6. Drugs Affecting Bone Metabolism
7. Other Endocrine Drugs
>>
0. Hypothalamic&Ant Pituit Hormone&Antioest
0. Posterior Pituitary Hormones&Antagonists
(Click to View Drug List)
Cost
Cost
Packs
Packs
Items
Items
Loading…
Summary:
Formulary Notes (BNF Chapter)
Formulary Notes (BNF Chapter)
NICE Guidance (3)
NICE Guidance (3)
Other Links (0)
Other Links (0)
Important Local Documents (5)
Important Local Documents (5)
Notes for: Endocrine system
Last edited [17/05/2024 08:42:39]
NICE NG28 Type 2 diabetes in adults: management
NICE NG17 Type 1 diabetes in adults: diagnosis and management
NG18 Diabetes (type 1 and type 2) in children and young people
: diagnosis and management
Semaglutide
(
Ozempic)
setting
pre
-
set
quantities in
GP
pr
actice systems to prevent overprescribing
Guidelines for Blood Glucose Monitoring in Adults 2024
NICE Guidance (BNF Sub Paragraph Level) for - Posterior Pituitary Hormones&Antagonists
11/01/2016
TA358: Tolvaptan for treating autosomal dominant polycystic kidney disease
NICE Guidance (BNF Chapter Level) for - Endocrine system
16/08/2023
Semaglutide for managing overweight and obesity NICE TA875
09/08/2024
TA863 Somatrogon for treating growth disturbance in children and young people aged 3 years and over
No links available
Important Local Documents (BNF Chapter Level) for - Endocrine system
23/10/2020
NHS Kernow lancets factsheet September 2020
19/11/2021
NHS Kernow home blood glucose testing leaflet October 2021
31/10/2022
Glucagon-like peptide-1 (GLP-1) analogue factsheet 2022
10/03/2023
Insulin needle factsheet Cornwall ICB
10/08/2020
NHS Kernow diabetes and frailty guidance June 2020
Loading…
Cornwall Joint Formulary Recommended Choices
(...Top)
Displaying 13 Drugs
Key:
First Line Drugs
Second Line Drugs
Specialist advised
Specialist Initiated Drugs
Hospital Only Drugs
Discouraged
No comment available
Name
Tariff
BNF Sub Paragraph
Desmopressin tablet
200 mcg tab Pack of 30
£19.93
Posterior Pituitary Hormones&Antagonists
Desmopressin Nasal Spray (Desmospray)
10 mcg / spray (60 sprays / 6ml pack) Pack of 1
£25.02
Posterior Pituitary Hormones&Antagonists
Desmopressin Acetate (Desmotabs)
200 mcg tab Pack of 30
£29.43
Posterior Pituitary Hormones&Antagonists
Desmopressin Nasal Spray
10 mcg / spray (60 sprays / 6ml pack) Pack of 1
£33.40
Posterior Pituitary Hormones&Antagonists
Desmopressin Acetate (DDAVP)
200 mcg tab Pack of 90
£88.23
Posterior Pituitary Hormones&Antagonists
Tolvaptan (Jinarc)
15 mg tablets Pack of 7
-
Posterior Pituitary Hormones&Antagonists
Tolvaptan (Jinarc)
30 mg tablets Pack of 7
-
Posterior Pituitary Hormones&Antagonists
Desmopressin (Octim)
150 mcg / ml nasal spray Pack of 2
-
Posterior Pituitary Hormones&Antagonists
Tolvaptan (Samsca)
15 mg tab Pack of 10
-
Posterior Pituitary Hormones&Antagonists
NICE TA358 Tolvaptan is recommended as an option for the treatment of autosomal dominant polycystic kidney disease in adults when specified criteria are met (October 2015) Hyponatraemia secondary to SIADH in patients requiring cancer chemotherapy. Commissioned by NHS England
Tolvaptan (Samsca)
30 mg tab Pack of 10
-
Posterior Pituitary Hormones&Antagonists
NICE TA358 Tolvaptan is recommended as an option for the treatment of autosomal dominant polycystic kidney disease in adults when specified criteria are met (October 2015) Hyponatraemia secondary to SIADH in patients requiring cancer chemotherapy. Commissioned by NHS England
Tolvaptan (Jinarc)
45 mg tablets and Jinarc 15mg tablets Pack of 56
-
Posterior Pituitary Hormones&Antagonists
Tolvaptan (Jinarc)
60 mg tablets and Jinarc 30mg tablets Pack of 56
-
Posterior Pituitary Hormones&Antagonists
Tolvaptan (Jinarc)
90 mg tablets and Jinarc 30mg tablets Pack of 56
-
Posterior Pituitary Hormones&Antagonists
© Kernow Clinical Commissioning Group 2024 - All Rights Reserved
The Sedgemoor Centre, Priory Road, St Austell, Cornwall, PL25 5AS